Functional heartburn, nonerosive reflux disease, and reflux esophagitis are all distinct conditions - A debate: Con

Current Treatment Options in Gastroenterology

Volumn 10, Issue 4, 2007, Pages 305-311

  Fry, Lucía C ^b   Mönkemüller, Klaus ^b   Malfertheiner, Peter ^a  

^a UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CISAPRIDE; ESOMEPRAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PLACEBO; SUCRALFATE; TRICYCLIC ANTIDEPRESSANT AGENT;

ABDOMINAL PAIN; BARRETT ESOPHAGUS; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DYSPEPSIA; ENDOSCOPY; ENTERITIS; ESOPHAGITIS; ESOPHAGUS MOTILITY; ESOPHAGUS PRESSURE; FOLLOW UP; GASTROESOPHAGEAL REFLUX; GASTROSCOPY; HEARTBURN; HUMAN; LOW DRUG DOSE; PATHOPHYSIOLOGY; REFLUX ESOPHAGITIS; REVIEW; SLEEP DISORDER;

EID: 34547556822     PISSN: 10928472     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11938-007-0073-4     Document Type: Review

References (30)

1. Vakil N, van Zanten SV, Kahrilas P, et al.: The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006, 101:1900-1920.
2. Locke GR, Talley J, Fett SL, et al.: Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997, 112:1448-1456.
3. Klauser AG, Schindlbeck NE, Muller-Lissner SA: Symptoms in gastro-oesophageal reflux disease. Lancet 1990, 335:205-208.
4. Labenz J, Nocon M, Lind T, et al.: Prospective follow-up data from the ProGERD study suggest that GERD is not a categorial disease. Am J Gastroenterol 2006, 101:2457-2462.
5. Ronkainen J, Aro P, Storskrubb T, et al.: High prevalence of gastroesophageal reflux symptoms and esophagitis with or without symptoms in the general adult Swedish population: a Kalixanda study report. Scand J Gastroenterol 2005, 40:275-285.
6. Labenz J, Malfertheiner P: Treatment of uncomplicated reflux disease. World J Gastroenterol 2005, 11:4291-4299.
7. Martinez SD, Malagon IB, Garewal HS, et al.: Non-erosive reflux disease (NERD) - acid reflux and symptom patterns. Aliment Pharmacol Ther 2003, 17:537-545.
8. Malfertheiner P, Lind T, Willich S, et al.: Prognostic influence of Barrett's oesophagus and Helicobacter pylori infection on healing of erosive gastro-oesophageal reflux disease (GORD) and symptom resolution in non-erosive GORD: report from the ProGORD study. Gut 2005, 54:746-751.
9. Trivedi A, Long JD: Heartburn refractory to proton-pump inhibitors. Curr Treat Options Gastroenterol 2007, 10:47-56.
10. Venables TL, Newland RD, Patel AC, et al.: Omeprazole 10 milligrams once daily, omeprazole 20 mg once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms in general practice. Scand J Gastroenterol 1997, 32:965-973.
11. Lind T, Havelund T, Carlsson R, et al.: Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997, 32:974-979.
12. Katz PO, Castell DO, Levine D: Esomeprazole resolves chronic heartburn in patients without erosive oesophagitis. Aliment Pharmacol Ther 2003, 18:875-883.
13. Armstrong D, Talley NJ, Lauritsen K, et al.: The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazole. Aliment Pharmacol Ther 2004, 20:413-421.
14. Kahrilas PJ: Refractory heartburn. Gastroenterology 2003, 124:1941-1945.
15. Carlsson R, Dent J, Watts R, et al.: Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol 1998, 10:119-124.
16. Lind T, Havelund T, Lundell L, et al.: On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis - a placebo-controlled randomized trial. Aliment Pharmacol Ther 1999, 13:907-914.
17. Talley NJ, Lauritsen K, Tunturi-Hihnala H, et al.: Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oseophageal reflux disease: a controlled trial of 'on-demand' therapy for 6 months. Aliment Pharmacol Ther 2001, 15:347-354.
18. Talley NJ, Venables TL, Green JR, et al.: Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 months. Eur J Gastroenterol Hepatol 2002, 14:857-863.
19. Tsai HH, Chapman R, Shepherd A, et al.: Esomeprazole 20 mg on-demand is more acceptable to patients than continuous lansoprazole 15 mg in the long-term maintenance of endoscopy-negative gastro-oesophageal reflux patients: the COMMAND Study. Aliment Pharmacol Ther 2004, 20:657-665.
20. Bayerdörffer E, Sipponen P, Bigard M, et al.: Esomeprazole 20 mg continuous versus on demand treatment of patients with endoscopy-negative reflux disease (ENRD) [abstract]. Gut 2004, 53 (Suppl 4):A106.
21. Castell DO, Kahrilas PJ, Richter JE, et al.: Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002, 97:575-583.
22. Fennerty MB, Johanson JF, Hwang C, Sostek M: Efficacy of esomeprazole 40 mg vs. lansoprazole 30 mg for healing moderate to severe erosive oesophagitis. Aliment Pharmacol Ther 2005, 21:455-463.
23. Labenz J, Armstrong D, Lauritsen K, et al.: A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study. Aliment Pharmacol Ther 2005, 21:739-746.
24. Schmitt C, Lightdale CJ, Hwang C, Hamelin B: A multicenter, randomized, double-blind, 8-week comparative trial of standard doses of esomeprazole (40 mg) and omeprazole (20 mg) for the treatment of erosive esophagitis. Dig Dis Sci 2006, 51:844-850.
25. Lightdale CJ, Schmitt C, Hwang C, Hamelin B: A multicenter, randomized, double-blind, 8-week comparative trial of low-dose esomeprazole (20 mg) and standard-dose omeprazole (20 mg) in patients with erosive esophagitis. Dig Dis Sci 2006, 51:852-857.
26. Sjostedt S, Befrits R, Sylvan A, et al.: Daily treatment with esomeprazole is superior to that taken on-demand for maintenance of healed erosive oesophagitis. Aliment Pharmacol Ther 2005, 22:183-191.
27. Johnson DA, Benjamin SB, Vakil NB, et al.: Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety. Am J Gastroenterol 2001, 96:27-34.
28. Vakil NB, Shaker R, Johnson DA, et al.: The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety. Aliment Pharmacol Ther 2001, 15:927-935.
29. Devault KR, Johanson JF, Johnson DA, et al.: Maintenance of healed erosive esophagitis: a randomized six-month comparison of esomeprazole twenty milligrams with lansoprazole fifteen milligrams. Clin Gastroenterol Hepatol 2006, 4:852-859.
30. Goh KL, Benamouzig R, Sander P, et al.: Efficacy of pantoprazole 20 mg daily compared with esomeprazole 20 mg daily in the maintenance of healed gastroesophageal reflux disease: a randomized, double-blind comparative trial - the EMANCIPATE study. Eur J Gastroenterol Hepatol 2007, 19:205-211.